Insights Into Acute Myeloid Leukemia (AML) 2024
Perspectives of community physicians on the treatment of AML
Florida – February 10, 2024
Faculty Chair
Elias Jabbour, MD
MD Anderson Cancer Center, Houston, TX, USA
Southwest – February 23, 2024
Faculty Chair
Elias Jabbour, MD
MD Anderson Cancer Center, Houston, TX, USA
National – May 23, 2024
Faculty Chair
Elias Jabbour, MD
MD Anderson Cancer Center, Houston, TX, USA
National – September 17, 2024
Faculty Chair
Margaret Kasner, MD
Jefferson Health, Philadelphia, PA, USA
National – September 30, 2024
Faculty Chair
Sergio Giralt, MD
Memorial Sloan Kettering Cancer Center, New York, NY, USA
More Information
- Tampa, FL
- Florida
More Information
- Scottsdale, AZ
- Arizona, Colorado, Nevada, New Mexico, Southern California, Utah
More Information
- Virtual
- Washington, Nevada, California, Florida, Georgia, North Carolina, New Jersey, Indiana, Pennsylvania, Maine
More Information
- Philadelphia, PA
- Connecticut, Delaware, District of Columbia, Maine, Maryland, Massachusetts, New Hampshire, New Jersey, New York, Pennsylvania, Rhode Island, Vermont
More Information
- Virtual
- National
REPORT SNAPSHOT
- A moderated roundtable discussion focusing on the treatment of AML
- Disease state and data presentations are developed in conjunction with a national or regional oncology expert
- Insights on the following therapies will be obtained: venetoclax, gilteritinib, CC-486, azacitidine, cytarabine and daunorubicin (ie, 7+3), CPX-351, ivosidenib, gemtuzumab ozogamicin, midostaurin, and sorafenib
GEOGRAPHIC REPRESENTATION & CONTENT DEVELOPMENT
- Data collection is accomplished through use of audience response system questioning and moderated discussion
- The group of advisors comprises 10–15 medical oncologists representative of each region
